Skip to main content

Table 3 Results of the multivariate linear mixed models for the change in fasting glucose level

From: Effect of statins on fasting glucose in non-diabetic individuals: nationwide population-based health examination in Korea

 

Coefficient (β)

Standard error

p

Variables at baseline

 Sex (male)

0.111

0.002

< 0.001

 Age (years)

0.003

< 0.001

< 0.001

 Baseline fasting glucose (mmol/L)

− 0.764

0.001

< 0.001

Repeatedly measured variables at NHIS health examination

 Systolic blood pressure (per 10 mmHg)

0.028

< 0.001

< 0.001

 Body mass index (kg/m2)

0.023

< 0.001

< 0.001

 Current smoker

0.021

0.002

< 0.001

Alcohol consumption, frequency per week (times)

 < 1

Ref

  

 1–2

0.034

0.002

< 0.001

 3–4

0.094

0.002

< 0.001

 ≥ 5

0.116

0.003

< 0.001

Exercise, days per week (days)

 < 1

Ref

  

 1–4

− 0.005

0.001

< 0.001

 ≥ 5

− 0.011

0.002

< 0.001

Household income

 Q1, low

Ref

  

 Q2, middle

− 0.004

0.002

0.015

 Q3, high

− 0.011

0.002

< 0.001

Time period from baseline to each health examination (year)

0.035

< 0.001

< 0.001

PDC by any statina

0.093

0.007

< 0.001

PDC by fibrateb

0.022

0.025

0.387

PDC by ezetimibe

0.046

0.045

0.314

anDDD by any statinc

0.119

0.009

< 0.001

  1. Data are derived from the linear mixed models for the change in fasting glucose (mmol/L). These variables were included as fixed-effect variables
  2. PDC proportion of days covered by statins during the time period from baseline to serial health examination (ranged from 0 to 1, treated as a continuous variable)
  3. aValue is the estimated change in fasting glucose when whole time period is covered by statins (PDC = 1)
  4. bBezafibrate, ciprofibrate, etofibrate, fenofibrate, and gemfibrozil
  5. cWhen ‘anDDD by any statin’ were included in the multivariate linear mixed model instead of ‘PDC by any statin’